InsiderTrades.com logo
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.
Rajesh Malik net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Rajesh Malik Biography and Net Worth

Insider of G1 Therapeutics

Dr. Malik joined G1 in 2014. In his role as Chief Medical Officer, he leads the company’s clinical development, medical affairs, regulatory affairs, biometrics, translational medicine and preclinical teams. Previously, he served as Chief Medical Officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as Chief Medical Officer at Adherex Technologies, where he directed the company's global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb. Dr. Malik currently serves on the board of directors of Meryx, Inc. and POINT Biopharma Global. 

Dr. Malik received his M.D. from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at the Children's Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.

What is Rajesh Malik's net worth?

The estimated net worth of Rajesh Malik is at least $1.22 million as of February 12th, 2024. Dr. Malik owns 169,938 shares of G1 Therapeutics stock worth more than $1,215,057 as of December 29th. This net worth estimate does not reflect any other assets that Dr. Malik may own. Additionally, Dr. Malik receives an annual salary of $596,370.00 as Insider at G1 Therapeutics. Learn More about Rajesh Malik's net worth.

How old is Rajesh Malik?

Dr. Malik is currently 65 years old. There are 6 older executives and no younger executives at G1 Therapeutics. Learn More on Rajesh Malik's age.

What is Rajesh Malik's salary?

As the Insider of G1 Therapeutics, Inc., Dr. Malik earns $596,370.00 per year. There are 2 executives that earn more than Dr. Malik. The highest earning executive at G1 Therapeutics is Mr. John E. Bailey Jr., CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Rajesh Malik's salary.

How do I contact Rajesh Malik?

The corporate mailing address for Dr. Malik and other G1 Therapeutics executives is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. G1 Therapeutics can also be reached via phone at (919) 213-9835 and via email at [email protected]. Learn More on Rajesh Malik's contact information.

Has Rajesh Malik been buying or selling shares of G1 Therapeutics?

Rajesh Malik has not been actively trading shares of G1 Therapeutics within the last three months. Most recently, Rajesh Malik sold 28,600 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a transaction totalling $132,132.00. Following the completion of the sale, the insider now directly owns 169,938 shares of the company's stock, valued at $785,113.56. Learn More on Rajesh Malik's trading history.

Who are G1 Therapeutics' active insiders?

G1 Therapeutics' insider roster includes John Bailey, Jr. (CEO), James Hanson (General Counsel), Rajesh Malik (Insider), and Mark Velleca (Director). Learn More on G1 Therapeutics' active insiders.

Are insiders buying or selling shares of G1 Therapeutics?

In the last year, insiders at the sold shares 11 times. They sold a total of 89,808 shares worth more than $326,623.24. The most recent insider tranaction occured on July, 5th when insider Andrew Perry sold 1,337 shares worth more than $3,355.87. Insiders at G1 Therapeutics own 6.1% of the company. Learn More about insider trades at G1 Therapeutics.

Information on this page was last updated on 7/5/2024.

Rajesh Malik Insider Trading History at G1 Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2024Sell28,600$4.62$132,132.00169,938View SEC Filing Icon  
1/3/2024Sell3,019$3.12$9,419.28170,659View SEC Filing Icon  
12/11/2023Sell33,839$3.41$115,390.99136,378View SEC Filing Icon  
9/13/2022Sell18,000$15.71$282,780.0073,207View SEC Filing Icon  
4/22/2021Sell15,000$22.07$331,050.00View SEC Filing Icon  
3/23/2021Sell15,000$21.94$329,100.00View SEC Filing Icon  
1/22/2021Sell15,000$20.64$309,600.00View SEC Filing Icon  
12/10/2020Sell9,000$20.06$180,540.0038,200View SEC Filing Icon  
12/17/2018Sell3,776$30.00$113,280.00View SEC Filing Icon  
11/15/2018Sell3,776$39.75$150,096.00View SEC Filing Icon  
9/17/2018Sell3,776$66.08$249,518.08View SEC Filing Icon  
6/15/2018Sell3,776$44.31$167,314.56View SEC Filing Icon  
3/15/2018Sell3,776$38.18$144,167.68View SEC Filing Icon  
2/15/2018Sell3,776$20.00$75,520.00View SEC Filing Icon  
1/16/2018Sell3,776$22.96$86,696.96View SEC Filing Icon  
See Full Table

Rajesh Malik Buying and Selling Activity at G1 Therapeutics

This chart shows Rajesh Malik's buying and selling at G1 Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

G1 Therapeutics Company Overview

G1 Therapeutics logo
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $7.15
Low: $7.15
High: $7.15

50 Day Range

MA: $7.13
Low: $7.08
High: $7.15

2 Week Range

Now: $7.15
Low: $1.08
High: $7.19

Volume

N/A

Average Volume

1,701,154 shs

Market Capitalization

$373.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.